Abstract. In the present study, we investigated the roles and molecular mechanism of 10-gingerol, a phenolic compound isolated from *Zingiber officinale*, in regulating cell proliferation and invasion of MDA-MB-231 breast cancer cells. 10-gingerol treatment inhibited cell proliferation through downregulation of cell cycle regulatory proteins such as cyclin-dependent kinases and cyclins, and subsequent induction of G1 phase arrest. In addition, 10-gingerol treatment blocked cell invasion in response to mitogenic stimulation. These antitumor activities of 10-gingerol were mediated through inactivation of Akt and p38MAPK activity, and suppression of epidermal growth factor receptor expression. Collectively, these findings demonstrate the pharmacological roles of 10-gingerol in regulating breast cancer cell growth and progression, and suggest further evaluation and development as a potential therapeutic agent for the prevention and treatment of breast cancer.

Introduction

Breast cancer is the most common type of cancer and the leading cause of cancer-related death in women (1). Approximately 70% of breast cancer patients are positive for estrogen receptor (ER) and these patients are suitable for anti-estrogen therapy. ER-negative breast cancer is often more malignant and aggressive than ER-positive breast cancer (2,3). In addition, overexpression of epidermal growth factor receptor (EGFR) or human EGFR-2 (HER2) is well correlated to recurrent and metastatic breast cancers (4,5). These receptors and their downstream signaling pathways are widely appreciated as the therapeutic targets for breast cancer.

Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteases which are degrading all components of extracellular matrix as well as cell surface molecules, leading to regulating a variety of biological responses including cell migration, invasion, proliferation, apoptosis and angiogenesis (6-9). A number of MMPs are highly expressed in cancer tissue from breast cancer patients, and these expression patterns are closely associated with aggressive phenotypes and poor survival (10). Although early detection methods and multimodal approaches for breast cancer treatment have been made, there has been only modest progress in improving clinical outcomes for women with metastases. Therefore, detailed understanding of the biology and its molecular mechanism underlying the progression of the disease may provide insights into therapeutic targets and strategies for the treatment of breast cancer.

Ginger (*Zingiber officinale* Roscoe, Zingiberaceae) is a natural dietary rhizome that is widely used as a traditional medicinal herb as well as a flavoring agent. Ginger has various bioactive components such as gingerols, shogaols, paradols and zingerone, indicating the pharmacological roles in mediating anti-inflammatory and antitumor activities (11-14). Among the bioactive ingredients from ginger, 6-gingerol and 6-shogaol have been extensively reported to exert antitumor activities in a variety of cancers by inhibition of cell proliferation, migration and invasion or induction of apoptosis (15-20). 10-gingerol, one of the main phenolic compounds isolated from ginger, has been reported to possess antitumor activity against ovarian, colon, lung and prostate cancer cells by inhibition of cell proliferation or induction of apoptosis (21,22), however, the effects and molecular mechanisms of 10-gingerol on breast cancer cell growth and progression are poorly understood. In the present study, we investigated the regulatory effects and signaling pathways of 10-gingerol on cell proliferation and invasion in MDA-MB-231 breast cancer cells.

Materials and methods

Cell culture conditions. Human breast cancer cells (MDA-MB-231) from American Type Culture Collection (Manassas, VA, USA) were grown in 10% fetal bovine
serum-Dulbecco's modified Eagle's medium (FBS-DMEM) (HyClone Laboratories, Logan, UT, USA).

**Preparation of ginger extract and isolation of 10-gingerol.** The dried *Zingiber officinale* (*Z. officinale*) was purchased from Gyeong-dong Oriental Medicine Market (Seoul, Republic of Korea), identified by Professor Joa Sub Oh (College of Pharmacy, Dankook University), and deposited at the herbarium of Gyeonggi Biocenter (Suwon, Republic of Korea). One thousand two hundred grams of *Z. officinale* were extracted three times with 15 liters of ethanol at room temperature for 24 h. The extract was concentrated, suspended in water, and then partitioned three times with 1.5 liters of n-hexane. The n-hexane extract (24 g) was subjected to silica gel column chromatography (Kieselgel 60, 70-230 mesh, 9x25 cm). Among eight fractions eluted from column chromatography, the sixth fraction (0.4 g) was further separated by semi-preparative HPLC (YMC-Pack ODS A column, 250x20 mm I.D.) eluting with acetonitrile-water (acetonitrile gradient from 50 to 100%) at a flow speed of 20 ml/min to yield (S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-tetradecanol (10-gingerol, 22.5 mg). 1H- and 13C-NMR spectra were recorded on a Varian 500 MHz NMR spectrometer (Bruker, Billerica, MA, USA).

**Spectrometric analysis of 10-gingerol.** 1H-NMR (CDCl3, 500 MHz) δ 6.83 (1H, d, J=8.0 Hz, H-5'), 6.69 (1H, d, J=2.0 Hz, H-2'), 6.67 (1H, dd, J=8.0, 2.0 Hz, H-6), 4.03 (1H, m, H-5), 3.88 (3H, s, OCH3), 2.84 (2H, brd, J=7.5 Hz, H-1), 2.75 (2H, brd, J=7.5 Hz, H-2), 2.58 (1H, dd, J=17.5, 3.0 Hz, H-4b), 2.50 (1H, dd, J=17.0, 9.0 Hz, H-4a), 1.49 (2H, m, H-6), 1.27-1.51 (14H, m, H-7-H-13), 0.89 (3H, t, J=7.0 Hz, H-14); 13C-NMR (CDCl3, 125 MHz) δ 211.5 (C-3), 146.4 (C-3'), 144.0 (C-4'), 132.6 (C-1'), 120.7 (C-6'), 114.4 (C-5'), 111.0 (C-2'), 67.7 (C-5), 55.9 (OCH3), 49.4 (C-4'), 45.4 (C-2'), 36.5 (C-6), 31.9 (C-1), 29.6 (C-9), 29.5 (C-8), 29.3 (C-10), 29.28 (C-11), 25.5 (C-7), 22.7 (C-13), 14.1 (C-14). The structure of 10-gingerol is presented in Fig. 1A.

**Reagents.** The following pharmacological agents and antibodies were purchased from commercial sources: LY294002 (Merck Millipore, Billerica, MA, USA); SB203580 (Cayman Chemical, Ann Arbor, MI, USA); anti-phospho-extra-cellular signal-regulated kinase (ERK) (T202/Y204), anti-phospho-Akt (S473), anti-phospho-p70S6K (T421/S424) and anti-phospho-p38 mitogen-activated protein kinase (p38MAPK) (T180/Y182) (Cell Signaling, Beverly, MA, USA); anti-phospho-p38 MAPK, anti-phospho-p38, anti-phospho-p38, anti-phospho-Cdk4, anti-Cdk2, anti-cyclin D, anti-cyclin E, anti-actin antibodies, and mouse and rabbit IgG-horseradish peroxidase conjugates (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

**Cell proliferation assay.** Subconfluent MDA-MB-231 cells, plated on 6-well plates (5x10^4 cells/well), were pretreated with 10-gingerol at different concentrations (0.1-10 µM) for 30 min, followed by 10% serum stimulation for 24 h. The results from triplicate determinations (mean ± standard deviation) are presented as the fold-increase of untreated controls. Statistical significance is indicated (*P<0.05, compared with 10% serum-treated cells).

**Cell cycle analysis.** Serum-starved MDA-MB-231 cells, plated on 6-well plates (5x10^4 cells/well), were pretreated with 10-gingerol (10 µM) for 30 min, followed by 10% FBS for 24 h. Cells were harvested with trypsin-EDTA, rinsed with phosphate buffered saline (PBS), and then fixed with ice-cold 70% ethanol for 3 h. After washing with PBS, cells were stained with Muse™ cell cycle reagent. The profile of cells in the G0/G1, S and G2/M phases of the cell cycle was analyzed with a Muse™ cell analyzer (Merck Millipore) (25).

**Western blot analysis.** Serum-starved cells in 100 mm dishes (BD Biosciences) were incubated for 15 min or 24 h in 10% FBS in the presence or absence of 10-gingerol. Cells were rinsed twice with ice-cold PBS and lysed by incubation in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 100 µg/ml 4-(2-amino-ethyl) benzenesulfonyl fluoride, 10 µg/ml aprotonin, 1 µg/ml pepstatin A, 0.5 µg/ml leupeptin, 80 mM β-glycerophosphate, 25 mM sodium fluoride and 1 mM sodium orthovanadate for 30 min at 4°C. Cell lysates were clarified at 13,000 x g for 20 min at 4°C, and the supernatants were subjected to western blot analysis as described previously (26,27). Bands of interest were integrated and quantified by the use of National Institutes of Health (NIH) ImageJ version 1.34s software.

**Invasion assay.** The upper side of the Transwell insert (Costar, 6.5 mm diameter insert, 8 µm pore size) (Corning Inc., Corning, NY, USA) was coated with 50 µl of 1 mg/ml.
Matrigel (BD Biosciences) diluted in serum-free DMEM at 37°C. Aliquots (100 μl) of MDA-MB-231 cells (6x10⁵ cells/ml) resuspended in serum-free DMEM were added to the upper compartment of the Matrigel-coated Transwell and 600 μl of serum-free DMEM were added to the lower compartment. After serum starvation for 2 h, MDA-MB-231 cells were pretreated with 10-gingerol (10 μM), LY294002 (10 μM) or SB203580 (5 μM) for 30 min, followed by serum stimulation for 14 h. The inserts were fixed with methanol and using a cotton-tipped swab the non-invasive cells were removed from the top of the membrane. After staining with 0.04% Giemsa solution (Sigma-Aldrich, St. Louis, MO, USA), the number of invasive cells was determined from six different fields using objective magnification, x200 (28).

Zymogram analysis. Activities of MMPs were measured by zymography (29,30). Aliquots of conditioned medium were diluted in sample buffer, and applied to 10% polyacrylamide gels containing 1 mg/ml gelatin (Sigma-Aldrich) as a substrate. After electrophoresis, the gels were incubated in 2.5% Triton X-100 for 1 h to remove SDS and allow re-naturalization of MMPs, and further incubated in developing buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM CaCl₂, and 150 mM NaCl for 15 h at 37°C. The gels were stained with 0.5% Coomassie Brilliant Blue R-250 in 30% methanol-10% acetic acid for 2 h and followed by destaining with 30% methanol-10% acetic acid. Gelatinolytic activities were detected as unstained bands against the background of the Coomassie Blue-stained gelatin.

Statistical analysis. Statistical analysis was performed using Student’s t-test and was based on at least three different experiments. The results were considered to be statistically significant at P<0.05.

Results

10-Gingerol inhibits cell proliferation via downregulation of cell cycle regulatory proteins. We first investigated the effect of 10-gingerol on cell proliferation in ER-negative MDA-MB-231 breast cancer cells. 10-gingerol treatment inhibited mitogen-stimulated cell proliferation in a dose-dependent manner (Fig. 1B), and did not alter cell viability at the highest concentration used in this study (data not shown), indicating that 10-gingerol-mediated inhibition of cell proliferation is not mediated by the induction of apoptosis or cytotoxicity. In addition, our initial experiments indicate that 10-gingerol markedly inhibited ER-positive MCF-7 breast cancer cell proliferation to levels similar to that observed in MDA‑MB‑231 cells (data not shown). These findings demonstrate the anti-proliferative activity of 10-gingerol in breast cancer cells, independently of ER expression status. We next examined the effect of 10-gingerol on the cell cycle by DNA content analysis (Fig. 2A). Mitogenic stimulation for 24 h increased the percentage of cells in S phase (6.3 vs. 14.9%) and G2/M phase (13.3 vs. 29.8%), and simultaneously decreased the percentage of cells in G1 phase (80.4 vs. 55.3%), compared with untreated controls. However, 10-gingerol prevented the increase in S phase (14.9 vs. 13.9%) and G2/M phase (29.8 vs. 22.3%), and the decrease in G1 phase (55.3 vs. 63.8%) associated with mitogenic stimulation. These observations suggest that 10-gingerol inhibits the transition from G1 phase of the cell cycle to S phase, resulting in G1 arrest, which is well correlated with inhibition of cell proliferation (Fig. 1B). Based on these findings, we analyzed the changes of cell cycle regulatory proteins in 10-gingerol-treated MDA-MB-231 cells. 10-Gingerol treatment markedly suppressed mitogen-induced...
JOO et al: ANTIMOR ACTIVITY OF 10-GINGEROL AGAINST MDA-MB-231 BREAST CANCER CELLS

expression of cyclin-dependent kinases (Cdks) and cyclins to levels observed in untreated controls (Fig. 2B). Collectively, these findings indicate that 10-gingerol downregulates the expression of cell cycle regulatory proteins, resulting in inhibition of cell cycle progression and proliferation.

10-Gingerol inhibits cell invasion. We next examined the effect of 10-gingerol on cell invasion which plays pivotal roles in cancer progression. 10-Gingerol treatment markedly inhibited mitogen-induced invasion of MDA-MB-231 cells (Fig. 3A). Expression and activation of MMPs have been reported to enhance cell migration and invasion by degrading the components of extracellular matrix and cell surfaces (6-9). Based on 10-gingerol-mediated inhibition of cell invasion, we examined the activity of MMPs in MDA-MB-231 cells. 10-gingerol treatment marginally inhibited the activity of MMP-2, but not MMP-9, suggesting that inhibition of cell invasion by 10-gingerol is mediated, at least in part, through the suppression of MMP-2 activity (Fig. 3B).

Regulatory effects of 10-gingerol on cell proliferation and invasion are mediated through inactivation of Akt- and p38MAPK-dependent signaling pathways. To investigate the molecular mechanism by which 10-gingerol modulates cell proliferation and invasion, we examined changes in activation of intracellular signaling pathways such as Akt, p70S6K, ERK and p38MAPK in 10-gingerol-treated MDA-MB-231 cells. Mitogenic stimulation increased the phosphorylation/activation of Akt, ERK and p38MAPK, but not that of p70S6K, as compared with unstimulated controls. 10-Gingerol treatment markedly inhibited the phosphorylation of Akt and p38MAPK in MDA-MB-231 cells (Fig. 4). Finally, pretreatment of cells with LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K)/Akt pathway, or SB203580, an inhibitor of p38MAPK pathway, mimicked the suppressive effects of 10-gingerol on cell proliferation and invasion in MDA-MB-231 cells (Fig. 5A and B). Co-treatment with 10-gingerol did not significantly enhance the anti-proliferative activity of these pharmacological inhibitors, indicating that 10-gingerol and these inhibitors may share similar roles and mechanisms of action in regulating cellular processes of MDA-MB-231 cells.

10-Gingerol suppresses the expression of EGFR. The EGFR is a receptor tyrosine kinase which is highly expressed or activated in various types of human cancers including breast cancer (4,31). Therefore, EGFR and its downstream signaling pathways have been known as key therapeutic targets for cancer treatment. 10-Gingerol treatment markedly suppressed mitogen-induced expression of EGFR in MDA-MB-231 cells to levels observed in unstimulated controls (Fig. 5C).
together, these observations suggest that anti-proliferative and anti-invasive activities of 10-gingerol in MDA-MB-231 breast cancer cells might be correlated with suppression of EGFR expression.

Discussion

Ginger has popularly been consumed as a flavoring agent and traditional medicinal herb for the treatment of a variety of disorders such as pain, inflammation, asthma, hypertension and diabetes through antioxidative, anti-inflammatory and anti-hyperglycemic activities (32). In addition, antitumor effects of ginger and its components including gingerols and shogaols have been reported in various types of human cancers (11-13,15-22). However, no pharmacological effects and detailed molecular mechanisms of 10-gingerol on breast cancer cell proliferation and invasion have been clearly investigated to date.

Data presented in this study show that 10-gingerol treatment markedly inhibits the proliferation of breast cancer cells through downregulation of cell cycle regulatory proteins such as Cdk5 and cyclins, and this anti-proliferative activity of 10-gingerol seems to be independent of ER expression status. Moreover, 10-gingerol strongly abrogates breast cancer cell invasion, which might be mediated partially through inhibition of MMP-2 activity. Previous studies demonstrate that 6-gingerol or 6-shogaol inhibits cell invasion in different cell lines including breast cancer and liver cancer by differential modulation of MMP-2 and MMP-9 activity (15,18,33). These findings indicate that the regulatory effect of bioactive phenolic components including 10-gingerol, 6-gingerol or 6-shogaol on MMP activity might be dependent on the cell/tissue types or the changes in expression of endogenous inhibitors, tissue inhibitors of metalloproteinases (34).

EGFR is frequently overexpressed in ER-negative breast cancer patients with aggressive phenotype and poor clinical outcome, indicating the potential role of EGFR and its down-stream signaling components as therapeutic targets for the treatment of ER-negative breast cancers (35). EGFR-dependent down-stream signaling pathways include the activation of PI3K/Akt, Ras/Raf/ERK, p38MAPK, c-Jun N-terminal kinase, phospholipase Cγ, and focal adhesion kinase, which are implicated in cell proliferation, survival, migration and invasion (4). In the present study we demonstrated that 10-gingerol-mediated inhibition of breast cancer cell proliferation and invasion is mediated through inactivation of Akt and p38MAPK as evidenced by treatment with LY294002 and SB203580, respectively. Furthermore, 10-gingerol treatment markedly suppressed the expression of EGFR in ER-negative MDA-MB-231 cells as well as ER-positive MCF-7 cells (data not shown). This finding is similar to the patterns of 10-gingerol inhibition of cell proliferation in both ER-negative MDA-MB-231 and ER-positive MCF-7 cells. In conclusion, we demonstrate for the first time that 10-gingerol inhibits mitogen-induced Akt and p38MAPK phosphorylation/activation and EGFR expression, leading to inhibition of breast cancer cell proliferation and invasion. These findings warrant further evaluation and preclinical development of 10-gingerol as a potent antitumor agent in combination with conventional or molecular targeted therapies for the treatment of breast cancer.

Acknowledgements

The present study was supported by the research fund of Dankook University in 2014.

References


